19 terminated. 19 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Terminated 19 |
| Phase 1 | 3 | Terminated 3 |
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease HRG2005 inhalation, Placebo to match HRG2005 inhalation, Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 82 | 2024-01-15 | 2025-12-22 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications Azithromycin, HP xenon (¹²⁹XE) - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Genentech, Inc. | 12 | 2021-11-16 | 2024-12-24 |
| A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) ION-827359, Placebo - Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Ionis Pharmaceuticals, Inc. | 60 | 2020-12-22 | 2022-12-20 |
| Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD) QBW251, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 54 | 2020-09-10 | 2024-06-20 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia QAW039, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 9 | 2019-05-21 | 2021-10-08 |
| A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 55 | 2016-03-01 | 2019-05-21 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD CHF6297 (Part 1 - SAD), Placebo (Part 1 - SAD), CHF6297 (Part 2 - MAD) - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Chiesi Farmaceutici S.p.A. | 118 | 2016-01-22 | 2020-04-17 |
| Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin - Chronic Obstructive Pulmonary Disease, Muscle Weakness | Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2014-04-16 | 2017-02-15 |
| Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease Roflumilast, Placebo - Chronic Obstructive Pulmonary Disease, Metabolic Syndrome | Phase 2 | Terminated | Laval University | 14 | 2013-02-01 | 2014-11-11 |
| Functional Applications of Hyperpolarized 129Xe MRI Hyperpolarized 129Xe gas - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Brigham and Women's Hospital | 1 | 2013-01-01 | 2018-04-17 |
| A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients AZD8683, Placebo, Tiotropium - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Terminated | AstraZeneca | 3 | 2012-10-01 | 2014-01-15 |
| Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD) Iloprost, Placebo - Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension | Phase 2 | Terminated | Actelion | 2 | 2012-03-01 | 2015-11-20 |
| Long-term Effects of Non-invasive Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients Functional Respiratory Imaging, Lung compliance measurement, Non-invasive ventilation (Respironics) - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | FLUIDDA nv | 40 | 2011-02-01 | 2014-01-16 |
| Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema tetomilast, placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 84 | 2009-03-01 | 2017-04-17 |
| A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Jazz Pharmaceuticals | 158 | 2007-04-01 | 2021-12-02 |
| Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012) Navarixin 1 mg, Navarixin 10 mg, Placebo to match navarixin - Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 99 | 2006-12-01 | 2019-01-02 |
| Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease azithromycin - Asthma, Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Johns Hopkins University | 18 | 2005-09-01 | 2013-05-13 |
| Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease Bisoprolol, Placebo - Heart Failure, Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | NHS Greater Glasgow and Clyde | 27 | 2005-03-01 | 2008-09-03 |
Pulmonary Disease, Chronic Obstructive (19) · Asthma (2) · Bronchitis, Chronic (1) · Eosinophilia (1) · Heart Failure (1) · Hypercapnia (1) · Hypertension, Pulmonary (1) · Metabolic Syndrome (1) · Muscle Weakness (1) · Smoking Cessation (1)
Chronic Disease (19) · Disease Attributes (19) · Lung Diseases (19) · Lung Diseases, Obstructive (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Respiratory Tract Diseases (19) · Bronchial Diseases (3) · Cardiovascular Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Respiratory Hypersensitivity (2) · Signs and Symptoms (2) · Behavior (1)
Azithromycin (2) · Roflumilast (2) · Bisoprolol (1) · Cholecalciferol (1) · Geritol (1) · Iloprost (1) · Inhalation (1) · Noninvasive Ventilation (1) · Sodium Chloride (1) · Tiotropium Bromide (1) · fevipiprant (1) · icenticaftor (1) · navarixin (1) · tetomilast (1)
Novartis Pharmaceuticals (2) · Actelion (1) · Arrowhead Pharmaceuticals (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chiesi Farmaceutici S.p.A. (1) · FLUIDDA nv (1) · Genentech, Inc. (1) · Ionis Pharmaceuticals, Inc. (1) · Jazz Pharmaceuticals (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Johns Hopkins University (1) · Laval University (1) · Merck Sharp & Dohme LLC (1)
United States (7) · United Kingdom (6) · Germany (4) · Poland (3) · Belgium (2) · Canada (2) · China (2) · Spain (2) · Australia (1) · Austria (1) · Czechia (1) · France (1) · Hungary (1) · Netherlands (1) · New Zealand (1)
Carin Jorup, MD (1) · Dave Singh, MD (1) · Francis G Dunn, MBChB MD (1) · Frederic Bodin, MD (1) · George W Chalmers, MBChB MD (1) · Jerry A Krishnan, MD, PhD (1) · Martin Mahoney (1) · Nathaniel M Hawkins, MBChB (1) · Peter Wijkstra, MD, PhD (1) · Roger Carter, BSc MSc PHD (1) · Samuel Patz, PhD (1)
2005 (1), 2015 (1), 2018 (1), P30CA016056 (1), P50CA090440 (1), R01HL096471 (1)